Verastem Unveils Promising VS-7375 Study Results

Verastem ( (VSTM) ) just unveiled an announcement.

On August 13, 2025, Verastem announced updated safety and efficacy data from the VS-7375 Phase 1/2 study conducted in China by GenFleet Therapeutics. The study, which included 142 patients with various advanced solid tumors, showed promising results, particularly in non-small cell lung cancer (NSCLC) patients with a KRAS G12D mutation. The overall response rate (ORR) for NSCLC patients at the recommended Phase 2 dose was 68.8%, with a disease control rate (DCR) of 93.8%. The data will be presented at the 2025 World Conference on Lung Cancer in Barcelona, Spain, highlighting the potential of VS-7375 as a significant treatment option for advanced KRAS G12D solid tumors.

The most recent analyst rating on (VSTM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.

Spark’s Take on VSTM Stock

According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.

Verastem’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative equity. However, positive technical indicators and recent corporate events, such as the $75M private placement, provide some optimism for future growth. Valuation remains constrained by negative earnings, but strategic initiatives and product development efforts could drive improvements. The stock represents a speculative opportunity, with potential upside if financial health and operational efficiencies improve.

To see Spark’s full report on VSTM stock, click here.

More about Verastem

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing new medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. and is dedicated to advancing novel small molecule drugs that inhibit critical cancer signaling pathways, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.

Average Trading Volume: 2,566,406

Technical Sentiment Signal: Hold

Current Market Cap: $505.3M

For detailed information about VSTM stock, go to TipRanks’ Stock Analysis page.